

PERSONAL INFORMATION **Wei Zhao**

WORK EXPERIENCE

- October 2014- Present **Professor**
Shandong University (China)
- November 2010- Present **Researcher**
INSERM (France)
- November 2009- Present **Clinical Pharmacologist**
Robert Debre University Hospital (France)

EDUCATION AND TRAINING

- September 2007-October 2010 **PhD**
Paris Descartes University (France)

ADDITIONAL INFORMATION

- Expertise** Pediatric Pharmacology Pharmacokinetics Pharmacometrics Pharmacogenetics Therapeutic Drug Monitoring
- Publications** 2020 1. Zhou Y, Du B, Kan M, Chen S, Tang BH, Nie AQ, Ye PP, Shi HY, Hao GX, Guo XL, Han QJ, Zheng Y, Zhao W #. Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration. *Pharm Res*. 2020;37(8):158. (IF 3.6) 2. Gao XB, Zheng Y, Yang F, Wang CH, Jiang ZH, Wu YE, Jacqz-Aigrain E, Ni SQ, Zhao W #. Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China. *Br J Clin Pharmacol*. 2020. (IF 3.8) 3. Khan MW, Wang YK, Wu YE, Tang BH, Kan M, Shi HY, Zheng Y, Xu BP, Shen AD, Jacqz-Aigrain E, Tian LY, Zhao W #. Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia. *Eur J Clin Pharmacol*. 2020 Jun 25. (IF 2.8) 4. Wang ZM, Chen XY, Bi J, Wang MY, Xu BP, Tang BH, Li C, Zhao W #, Shen AD. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis. *Antimicrob Agents Chemother*. 2020;64(8): e00760-20. (IF 4.6) 5. Kan M, Wu L, Zhou XW, Jiang YF, Wu YE, Shi HY, Hao GX, Zheng Y, Su LQ, Huang X, Zhao W #. Cefotiam Treatment in Children: Evidence of Subtherapeutic Levels. *Ther Drug Monit* 2020; Epub (IF 2.0) 6. Ye PP, Zheng Y, Du B, Liu XT, Tang BH, Kan M, Zhou Y, Hao GX, Huang X, Su LQ, Wang WQ, Yu F, Zhao W #. First dose in neonates: pharmacokinetic bridging study from juvenile mice to neonates for drugs metabolized by CYP3A. *Xenobiotica*. 2020;1-10. (IF 2.0) 7. Hao GX, Yuan XX, Guo W, Quan XY, Qi XJ, Wang TY, Zhao W #. Paediatric drugs trials in China. *BMJ Paediatr Open*. 2020;4(1):e000618. (IF 2.0) 8. Kan M, Wu YE, Li X, Dong YN, Du B, Guo ZX, Shi HY, Huang X, Su LQ, Wang WQ, Zheng Y, Zhao W #. An adapted LC-MS/MS method for the determination of free plasma concentration of cefoperazone in children: Age-dependent protein binding. *J Chromatogr B Analyt Technol Biomed Life Sci* 2020;1144:122081. (IF 2.9) 9. Guan Z, Jacobs G, van Pelt H, Van Gerven JMA, Burggraaf J, Zhao W #. PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva. *Pharmacol Res Perspect* 2020;8(2):e00574. (IF 3.0) 10. Shi HY, Wang K, Wang RH, Wu YE, Tang BH, Li X, Du B, Kan M, Zheng Y, Xu BP, Shen AD, Su LQ, Jacqz-Aigrain E, Huang X, Zhao W #. Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children. *J Antimicrob Chemother* 2020. Epub (IF 5.1) 11. Zhao Y, Yao BF, Kou C, Xu HY, Tang BH, Wu YE, Hao GX, Zhang XP, Zhao W #. Developmental Population Pharmacokinetics and Dosing

Optimization of Cefepime in Neonates and Young Infants. *Front Pharmacol* 2020;11:14. (IF 3.8)

12. Zhou Y, Wang L, Zhai XY, Wen L, Tang F, Yang F, Liu XT, Dong L, Zhi LJ, Shi HY, Hao GX, Zheng Y, Jacqz-Aigrain E, Wang TY, Zhao W #. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. *Br J Clin Pharmacol* 2020 Epub(IF 3.8) 13. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, Zhao W, De Cock P, de Wildt SN, Allegaert K, van den Anker J. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. *Eur J Pediatr* 2020;179(5):839-847. (IF 2.0) 14. Hao GX, Song LL, Zhang DF, Su LQ, Jacqz-Aigrain E, Zhao W #. Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. *Br J Clin Pharmacol* 2020;86(2):274-284. (IF 3.8) 15. Jing W, Zong Z, Tang B, Wang J, Zhang T, Wen S, Xue Y, Chu N, Zhao W #, Huang H. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China. *Antimicrob Agents Chemother* 2020;64(3):e01736-19. (IF 4.5) 16. Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C. Optimisation of vancomycin exposure in neonates based on the best level of evidence. *Pharmacol Res* 2020;154:104278. (IF 5.2) 2019 17. Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W #. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. *J Antimicrob Chemother.* 2019;74(8):2128-2138. (IF 5.2) 18. Yang XM, Leroux S, Storme T, Zhang DL, de Beaumais TA, Shi HY, Yang YL, Wang XL, Zhao W #, Jacqz-Aigrain E. BSA-Based Dosing Regimen of Caspofungin in Children: A Population Pharmacokinetics Confirmatory Study. *Antimicrob Agents Chemother* 2019;63(7):e00248-19 (IF 4.3) 19. Dong L, Zhai XY, Yang YL, Wang L, Zhou Y, Shi HY, Tang BH, Wu YE, Yang F, Wen L, Kong HX, Zhi LJ, Jacqz-Aigrain E, Zhao W #. Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. *Antimicrob Agents Chemother.* 2019;63(6). pii: e00006-19. (IF 4.2) 20. Qi H, Kou C, Qi YJ, Tang BH, Wu YE, Jin F, Luo XJ, Shen YH, Guo YJ, Qi X, Wang YC, Dong Q, Chen XK, Shi HY, Zheng Y, Zhao W #, Shen AD. Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants. *Int J Antimicrob Agents* 2019;53(3):347-351. (IF 4.3) 21. Tang BH, Wu YE, Kou C, Qi YJ, Qi H, Xu HY, Leroux S, Huang X, Zhou Y, Zheng Y, Jacqz-Aigrain E, Shen AD, Zhao W #. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. *Antimicrob Agents Chemother* 2019;63(2). pii: e02336-18. (IF 4.2) 22. Li Q, Wang K, Shi HY, Wu YE, Zhou Y, Kan M, Zheng Y, Hao GX, Yang XM, Yang YL, Su LQ, Wang XL, Jacqz-Aigrain E, Zhou J, Zhao W #. Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children. *Drug Des Devel Ther* 2019;13:4405-4411. (IF 3.2) 23. Facchin A, Elie V, Benyoub N, Magreault S, Maisin A, Storme T, Zhao W, Deschenes G, Jacqz-Aigrain E. Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children. *Antimicrob Agents Chemother* 2019; 63(12):e01192-19 (IF 4.2) 24. Li Q, Shi HY, Wang K, Kan M, Zheng Y, Hao GX, Yang XM, Yang YL, Su LQ, Zhao W #. Determination of Loratadine and Its Active Metabolite in Plasma by LC/MS/MS: An Adapted Method for Children Current Pharmaceutical Analysis 2019; Epub 2018 25. Liu S, Zheng Y, Wu X, Xu B, Liu X, Feng G, Sun L, Shen C, Li J, Tang B, Jacqz-Aigrain E, Zhao W #, Shen A. Early target attainment of azithromycin therapy in children with lower respiratory tract infections. *J Antimicrob Chemother.* 2018; 73(10):2846-2850. (IF 5.2) 26. Sun SZ, Wang L, Wu YE, Ma GL, Yao BF, Dong L, Jacqz-Aigrain E, Shi ZR, Zhao W #. Aciclovir CSF concentration in children with viral encephalitis: is it adequate? *J Antimicrob Chemother* 2018;73(9):2582-2583. (IF 5.2) 27. Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, Zhou Y, Wu YE, Qi H, Jacqz-Aigrain E, Shen AD, Zhao W #. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. *Antimicrob Agents Chemother* 2018;62(9). pii: e00686-18. (IF 4.2) 28. Dong Q, Leroux S, Shi HY, Xu HY, Kou C, Khan MW, Jacqz-Aigrain E, Zhao W #. Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. *Antimicrob Agents Chemother* 2018;62(5). pii: e00075-18 (IF 4.2) 29. Chen XK, Shi HY, Leroux S, Xu HY, Zhou Y, Zheng Y, Huang X, Li Y, Jacqz-Aigrain E, Zhao W #. Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants. *Antimicrob Agents Chemother* 2018;62(4). pii: e02448-17. (IF 4.2) 30. Shi ZR, Chen XK, Tian LY, Wang YK, Zhang GY, Dong L, Jirasomprasert T, Jacqz-Aigrain E, Zhao W #. Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants. *Antimicrob Agents Chemother* 2018;62(4). pii: e02486-17. (IF 4.2) 31. Zhao W, Leroux S, Biran V, Jacqz-Aigrain E. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. *Br J Clin Pharmacol* 2018; 84(5):997-1005. (IF 3.8) 32. Zhang DF, Hao GX, Li CZ, Yang YJ, Liu FJ, Liu L, Yuan XY, Li RH, Dong L, Dong Q, Jacqz-Aigrain E, Zhao W #. Off-label use of tacrolimus in children with

Henoch-Schönlein purpura nephritis: a pilot study. *Arch Dis Child* 2018;103(8):772-775. (IF 3.2)

33. Hao GX, Huang X, Zhang DF, Zheng Y, Shi HY, Li Y, Jacqz-Aigrain E, Zhao W #. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. *Br J Clin Pharmacol* 2018;84(8):1748-1756. (IF 3.8)

34. Zhi LJ, Wang L, Chen XK, Zhai XY, Wen L, Dong L, Jacqz-Aigrain E, Shi ZR, Zhao W #.. Population pharmacokinetics and dosing optimization of cefthiamidone in children with hematologic infection. *Drug Des Devel Ther* 2018;12:855-862. (IF 2.9)

35. Dong Q, Shi HY, Kou C, Huang X, Shen AD, Zhao W #. A microscale HPLC-UV method for the determination of latamoxef in plasma: An adapted method for therapeutic drug monitoring in neonates. *Biomed Chromatogr.* 2018;32(8):e4243. (IF 1.7)

36. Maksoud E, Koehl B, Facchin A, Ha P, Zhao W, Kaguelidou F, Benkerrou M, Mariani P, Faye A, Lorrot M, Jacqz-Aigrain E. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. *Antimicrob Agents Chemother.* 2018;62(4). pii: e00637-17. (IF 4.2)

37. Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Barin-Le Guellec C, Aurich B, Biran V, Dusang B, Goudjil S, Coopman S, Garcia Sanchez R, Zhao W, Manzoni P; FP7 TINN (Treat Infections in NeoNates) consortium. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. *Br J Clin Pharmacol.* 2018;84(9):1989-1999. (IF 3.8)

38. Lancia P, Adam de Beaumais T, Elie V, Garaix F, Fila M, Nobili F, Ranchin B, Testevuide P, Ulinski T, Zhao W, Deschênes G, Jacqz-Aigrain E. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. *Pediatr Nephrol.* 2018;33(6):1045-1055. (IF 2.5)

39. Wu XJ, Huang X, Shi HY, Chen XK, Dong Q, Hao GX, Li Y, Zheng Y, Zhao W. Determination of cefoperazone and sulbactam in serum by HPLC-MS/MS: An adapted method for therapeutic drug monitoring in children. *Biomed Chromatogr.* 2018; 32(4). (IF 1.7)

40. Wu YE, Wu XF, Kan M, Shi HY, Liu MJ, Chen XK, Dong Q, Huang X, Zheng Y, Zhao W. A Sensitive Microscale HPLC-UV Method for the Determination of Doxofylline and its Metabolites in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children. *Current Pharmaceutical Analysis* 2018; Epub 41.

Leroux S, Elie V, Zhao W, Magreault S, Jacqz-Aigrain E. Principles and applications of pharmacometrics in drug evaluation in children. *Therapie.* 2018 Apr;73(2):165-170.

2016 42. Leroux S, Biran V, Lopez E, Madeleneau D, Wallon C, Zana-Taieb E, Virlovet AL, Rioualen S, Jacqz-Aigrain E, Zhao W #. The clinical utility and safety of a model-based patient tailored dose of vancomycin in neonates. *Antimicrob Agents Chemother* 2016; 60(4):2039-2042. (IF 4.5)

43. Romos-Martin V, Johnson A, Livermore J, McEntee L, Goodwin J, Whalley S, Docobo-Perez F, Felton T, Zhao W, Jacqz-Aigrain E, Sharland M, Turner M, William H. Pharmacodynamics of vancomycin for Coagulase-Negative Staphylococcal infection: experimental basis for optimal use of vancomycin in neonates. *J Antimicrob Chemother* 2016; 71(4):992-1002. (IF 5.3)

44. Leroux S, Roué JM, Gouyon JB, Biran V, Zheng H, Zhao W, Jacqz-Aigrain E. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. *Antimicrob Agents Chemother* 2016 ;60(11):6626-6634. (IF 4.5)

45. Bourgeois T, Delezoide AL, Zhao W, Guimiot F, Adle-Biassette H, Durand E, Ringot M, Gallego J, Storme T, Barin-Le Guellec C, Kassai B, Turner M, Jacqz-Aigrain E. Safety study of ciprofloxacin in juvenile mice. *Regul Toxicol Pharmacol* 2016;74:161-169 (IF 2.0)

46. Leroux S, Zhao W, Biran V, Jacqz-Aigrain E. Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done. *Arch Pediatr* 2016;23(9):966-73.

2015 47. Leroux S, Turner MA, Barin-Le Guellec C, Hill H, van den Anker JN, Kearns GL, Jacqz-Aigrain E, Zhao W, # on behalf of the TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) consortiums. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design *Clin Pharmacokinet* 2015;54(12):1273-1285 (IF 5.5)

48. Brou NA, Jacqz-Aigrain E, Zhao W. # Cystatin C as a potential biomarker for dosing of renally excreted drugs. *Br J Clin Pharmacol* 2015;80(1):20-27. (IF 3.7)

49. Zhao W, Zhang D, Storme T, Baruchel A, Declèves X, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant hematological disease. *Br J Clin Pharmacol* 2015;80(5):1197-1207. (IF 3.7)

50. Lancia P, Jacqz-Aigrain E, Zhao W. # Choosing the right dose of tacrolimus. *Arch Dis Child* 2015;100(4):406-413. (IF 2.9)

51. Leroux S, Zhao W, Bétrémieux P, Pladys P, Saliba E, Jacqz-Aigrain E, on behalf of French Society of Neonatology. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. *Arch Dis Child* 2015;100(4):394-398. (IF 2.9)

52. Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. How to use vancomycin optimally in neonates: remaining questions. *Expert Rev Clin Pharmacol* 2015;8(5):635-648. (IF 2.1)

2014 53. Zhao W, Le Guellec C, Benjamin DK Jr, Hope WW, Bourgeois T, Watt KM, van den Anker JN, Matrot B, Saxen H, Hoppu K, Manzoni P, Jacqz-Aigrain E, on behalf of the TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) consortiums. First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole? *Clin Pharmacokinet* 2014; 53(11):1005-1018. (IF 5.5)

54. Zhang B, Fila M, Fakhoury M, Baudouin V, Deschênes G, Jacqz-Aigrain E, Zhao W.#

Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. *J Antimicrob Chemother* 2014; 69(4):1150-1151. (IF 5.5) 55. Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. *Antimicrob Agents Chemother* 2014; 58(6):3191-3199. (IF 4.5) 56. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellán C, Kassai B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E, on behalf of the TINN (Treat Infections in NeoNates) consortium. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than 3 months of age. *Antimicrob Agents Chemother* 2014; 58(11):6572-6580 (IF 4.5) 57. Zhao W, Leroux S, Jacqz-Aigrain E. Dosing individualization in children: Integration of pharmacometrics in clinical practice. *World J Pediatr* 2014; 10(3):197-203 (IF 1.1) 58. Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua OE. A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. *Br J Clin Pharmacol* 2014; 77(5):852-860. (IF 3.7) 59. Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua OE. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. *Br J Clin Pharmacol* 2014; 77(5):861-872. (IF 3.7) 60. Konofal E, Zhao W, Laouenan C, Lecendreux M, Kaguelidou F, Benadjaoud L, Mentré F, Jacqz-Aigrain E. Pilot phase 2 study of mazindol in children with Attention-Deficit/ Hyperactivity Disorder. *Drug Des Devel Ther* 2014; 8:2321-2332. (IF 3.0) 61. Liu F, Jiao AX, Wu XR, Zhao W, Yin QQ, Qi H, Jiao WW, Xiao J, Sun L, Shen C, Tian JL, Shen D, Jacqz-Aigrain E, Shen AD. Impact of Glutathione S-Transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. *Plos One* 2014; 9(12):e115410. (IF 3.5) 62. Elie V, Leroux S, Zhao W, Jacqz-Aigrain E. Pharmacokinetic variability and personalized therapy in children. *Arch Pediatr* 2014; 21(5) S1:16-17. 2013 63. Zhao W, Biran V, Jacqz-Aigrain E. Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates *Clin Pharmacokinet* 2013; 52(12):1127-1134. (IF 6.1) 64. Zhao W, Piana C, Danhof M, Burger D, Della Pasqua O, Jacqz-Aigrain E. Population pharmacokinetic of abacavir in infants, toddlers and children. *Br J Clin Pharmacol* 2013; 75(6):1525-1535. (IF 3.6) 65. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. External evaluation of population pharmacokinetic models of vancomycin in neonates: The transferability of published models to different clinical settings". *Br J Clin Pharmacol* 2013; 75(4):1068-1080. (IF 3.6) 66. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. *Arch Dis Child* 2013; 98(6):449-453. (IF 3.1) 67. Zhao W, Maisin A, Baudouin V, Fakhoury M, Storme T, Deschênes G, Jacqz-Aigrain E. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. *Eur J Clin Pharmacol* 2013; 69(5):1181-1185. (IF 2.7) 68. Zhao W, Fakhoury M, Baudouin V, Storme T, Maisin A, Deschênes G, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. *Eur J Clin Pharmacol* 2013; 69(2):189-195. (IF 2.7) 69. Zhao W, Jacqz-Aigrain E. The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results. *Ther Drug Monit* 2013;35(3): 416. (IF 2.2) 70. Ni SQ, Zhao W (co-first author), Wang J, Zeng S, Chen SQ, Zhao ZY. Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. *Acta Pharmacol Sin* 2013; 34(7):969-975. (IF 2.4) 71. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. *Semin Fetal Neonatal Med* 2013; 18(1):28-34. (IF 3.5) 2012 72. Zhao W, Fakhoury M, Baudouin V, Storme T, Deschênes G, Jacqz-Aigrain E. Pharmacogenetic determinants of the drug interaction between tacrolimus and omeprazole. *Ther Drug Monit* 2012; 34(6):739-741. (IF 2.5) 73. Zhao W, Hope WW, Manzoni P, Jacqz-Aigrain E. Optimizing micafungin dosing in children. *Pediatr Infect Dis J* 2012; 31(11):1211-1212. (IF 3.6) 74. Zhao W, Baudouin V, Fakhoury M, Storme T, Deschênes G, Jacqz-Aigrain E. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. *Transplantation* 2012; 93(7):e29-e30. (IF 4.0) 75. Zhao W, Fakhoury M, Fila M, Baudouin V, Deschênes G, Jacqz-Aigrain E. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. *Ther Drug Monit* 2012; 34(3):326-330. (IF 2.5) 76. Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E, on behalf of PENTA 15 study group. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV infected infants and toddlers. *Br J Clin Pharmacol* 2012; 73(4):641-650. (IF 3.0) 2011 77. Zhao W, Fakhoury M, Baudouin V, Maisin A, Deschênes G, Jacqz-Aigrain E. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. *Ther Drug Monit* 2011;

33(6):681-687. (IF 3.1) 78. Cella M, Zhao W, Jacqz-Aigrain E, Burger D, Danhof M, Della Pasqua O. Paediatric drug development: Are population models predictive of pharmacokinetics across paediatric populations?. *Br J Clin Pharmacol* 2011; 72(3):454-464. (IF 3.1) 79. Grondin C, Zhao W, Fakhoury M, Jacqz-Aigrain E. Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates. *Biomed Chromatogr* 2011; 25(7):827-832. (IF 1.5) 80. Zhao W, Jacqz-Aigrain E, on behalf of the CICP Network. French network of pediatric clinical investigation centers: new insights in European collaborative projects. *Journal of Pediatric Pharmacy* 2011; 17(1):1-5. 2010 81. Zhao W, Fakhoury M, Deschênes G, Roussey G, Brochard K, Niaudet P, Tsimaratos M, André JL, Cloarec S, Cochat P, Bensman A, Azougagh S, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. *J Clin Pharmacol* 2010; 50(11):1280-1291. (IF 3.4) 82. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. *Ther Drug Monit* 2010; 32(6):688-699. (IF 2.4) 83. Zhao W, Elie V, Baudouin V, Bensman A, André JL, Brochard K, Broux F, Cailliez M, Loirat C, Jacqz-Aigrain E. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. *Br J Clin Pharmacol* 2010; 69(4):358-366. (IF 3.2) 84. Jacqz-Aigrain E, Harrison L, Zhao W, Compagnucci A, Castro H, Farrelly L, Saidi Y, Hamadache D, Welch S, Wintergerst U, Forcat S, Hadjou G, Firtion G, Snowden W, Giaquinto C, Gibb D, Burger D (Writing Committee). Paediatric European Network for Treatment of AIDS. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-36 months. *Antivir Ther* 2010; 15(3):297-305. (IF 4.3) 2009 85. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. *Clin Pharmacol Ther* 2009; 86(6):609-618. (IF 7.6) 86. Zhao W, Baudouin V, Zhang D, Deschênes G, Le Guellec C, Jacqz-Aigrain E. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. *Clin Pharmacokinet* 2009; 48(5):321-328. (IF 4.2)

Projects

1. Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months (NeoVanc); EU FP7 project, grant agreement no. 602041. 2. Global research in pediatrics (GRIP); EU FP7 project, grant agreement no. 261060. 3. Treat infections in neonates (TINN1 and TINN2); EU FP7 projects, grant agreement no. 223614 and 260908. 4. Pediatric European network treatment AIDS laboratory network (PENTA LABNET); EU FP7 project, grant agreement no. 201057.

Memberships

MEMBERSHIPS Chinese Pharmacists Association (Vice president of TDM committee, 2018-) Chinese Research Hospital Association (Vice-president of pediatric committee, 2015-) European Society for Developmental Perinatal and Pediatric Pharmacology (Council Member 2015-) EDITORIAL RESPONSIBILITIES Executive Editor: *British Journal of Clinical Pharmacology* Associate Editor *BMJ Pediatrics Open*; *Frontiers in Pharmacology*; *Frontiers in Pediatrics*

Other Relevant Information